SCHEMBL3166192

SCHEMBL3166192

CC(=O)NC(CO)C(=O)NN

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.42
MAPT P10636 1/20 0.42
THRB P10828 1/20 0.42
ALOX15 P16050 1/20 0.42
NFKB1 P19838 1/20 0.42
PTGS2 P35354 1/20 0.42
THPO P40225 1/20 0.42
RECQL P46063 1/20 0.42
BLM P54132 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
ALDH1A1 P00352 2/20 0.41
GNPAT O15228 2/20 0.39
TGFBR1 P36897 3/20 0.38
HIF1A Q16665 1/20 0.37
SIRT6 Q8N6T7 1/20 0.35
SIRT1 Q96EB6 1/20 0.35
CPA1 P15085 1/20 0.35
CPA2 P48052 1/20 0.35
CPA4 Q9UI42 1/20 0.35
CA1 P00915 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27610443 0.81 KDM4E (0.61) KDM4EMAPTTHRBALOX15NFKB1
SCHEMBL21626384 0.80 TGFBR1 (0.42) KDM4ETGFBR1HIF1ACA1CA2
SCHEMBL21626383 0.80 TGFBR1 (0.42) KDM4ETGFBR1HIF1ACA1CA2
SCHEMBL13394103 0.80 KDM4E (0.43) KDM4EMAPTTHRBALOX15NFKB1
SCHEMBL10013379 0.80 KDM4E (0.43) KDM4EMAPTTHRBALOX15NFKB1
SCHEMBL11108853 0.79 REN (0.40) KDM4EMAPTTHRBALOX15NFKB1
SCHEMBL11108850 0.79 REN (0.40) KDM4EMAPTTHRBALOX15NFKB1
SCHEMBL14577477 0.78 ALDH1A1 (0.45) KDM4EMAPTTHRBALOX15NFKB1
SCHEMBL9293530 0.78 MAPT (0.38) KDM4EMAPTTHRBALOX15NFKB1
SCHEMBL2992278 0.78 KDM4E (0.47) KDM4EMAPTTHRBALOX15NFKB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8475765-B2 Hydroxyalkyl starch derivatives FRESENIUS KABI DEUTSCHLAND GMBH (DE) 2013-07-02 US disclosed
EP-2143736-B1 Hydroxyalkyl starch derivatives FRESENIUS KABI DE GMBH (DE) 2012-11-07 EP disclosed
CN-101133072-B Hydrogels for controlled release of bioactive materials FIRMENICH & CIE 2012-05-30 CN disclosed
US-20120046240-A9 Method of Producing Hydroxyalkyl Starch Derivatives FRESENIUS KABI DEUTSCHLAND GMBH (DE) 2012-02-23 US disclosed
US-20110054152-A1 Hydroxyalkyl Starch Derivatives FRESENIUS KABI DEUTSCHLAND GMBH (DE) 2011-03-03 US disclosed
EP-2272865-A2 Method of producing hydroxyalkyl starch derivatives Fresenius Kabi Deutschland GmbH (DE) 2011-01-12 EP disclosed
US-20100317609-A1 Method of Producing Hydroxyalkyl Starch Derivatives FRESENIUS KABI DEUTSCHLAND GMBH (DE) 2010-12-16 US disclosed
EP-1863827-B1 HYDROGELS FOR THE CONTROLLED RELEASE OF BIOACTIVE MATERIALS FIRMENICH & CIE (CH) 2010-03-03 EP disclosed
EP-2154160-A1 Hydroxyalkyl starch derivatives Fresenius Kabi Deutschland GmbH (DE) 2010-02-17 EP disclosed
EP-2143736-A1 Hydroxyalkyl starch derivatives Fresenius Kabi Deutschland GmbH (DE) 2010-01-13 EP disclosed
EP-2017287-A2 Method of producing hydroxyalkyl starch derivatives Fresenius Kabi Deutschland GmbH (DE) 2009-01-21 EP disclosed
US-20080057005-A1 HYDROGELS FOR THE CONTROLLED RELEASE OF BIOACTIVE MATERIALS FIRMENICH SA (CH) 2008-03-06 US disclosed
CN-101133072-A Hydrogels for controlled release of bioactive materials FIRMENICH & CIE (CH) 2008-02-27 CN disclosed
EP-1863827-A1 HYDROGELS FOR THE CONTROLLED RELEASE OF BIOACTIVE MATERIALS FIRMENICH SA (CH) 2007-12-12 EP disclosed
WO-2006100647-A1 HYDROGELS FOR THE CONTROLLED RELEASE OF BIOACTIVE MATERIALS FIRMENICH SA (CH) 2006-09-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110054152-A1 Hydroxyalkyl Starch Derivatives GRHPR, DCXR, HRH2 KDM4E 4409/4885MAPT 4518/4885THRB 3842/4885
US-20120046240-A9 Method of Producing Hydroxyalkyl Starch Derivatives HACL2, HAAO, LIPA KDM4E 3187/4885MAPT 4440/4885THRB 4762/4885
US-20100317609-A1 Method of Producing Hydroxyalkyl Starch Derivatives HACL2, HAAO, LIPA KDM4E 3187/4885MAPT 4440/4885THRB 4762/4885
US-20080057005-A1 HYDROGELS FOR THE CONTROLLED RELEASE OF BIOACTIVE MATERIALS GMPS, CGAS, PDE2A KDM4E 1558/4885MAPT 4136/4885THRB 2831/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.